Intramuscular vitamin K showed no clear difference in presence of PIVKA II at day 5: 0.2 mg IV versus 0.2 mg IM compared with intravenous vitamin K (low certainty).
Intramuscular vitamin K showed no clear difference in presence of PIVKA II at day 5: 0.2 mg IV versus 0.5 mg IM compared with intravenous vitamin K (low certainty).
Intramuscular vitamin K showed no clear difference in presence of PIVKA II at day 25: 0.2 mg IV versus 0.2 mg IM compared with intravenous vitamin K (low certainty).
Intramuscular vitamin K showed no clear difference in presence of PIVKA II at day 25 ‐ 0.2 mg IV versus 0.5 mg IM compared with intravenous vitamin K (low certainty).
Intramuscular vitamin K showed no clear difference in necrotizing enterocolitis ‐ 0.2 mg IV versus 0.2 mg IM compared with intravenous vitamin K (low certainty).
It is very uncertain whether barbiturate treatment changes death or major neurodevelopmental disability compared with placebo or no treatment (very low certainty).
Barbiturate treatment showed no clear difference in death compared with placebo or no treatment (low certainty).
It is very uncertain whether barbiturate treatment changes major neurodevelopmental disability compared with placebo or no treatment (very low certainty).
It is very uncertain whether barbiturate treatment changes cerebral palsy compared with placebo or no treatment (very low certainty).
It is very uncertain whether barbiturate treatment changes developmental delay compared with placebo or no treatment (very low certainty).
Barbiturate treatment may leads to lower seizures (clinical or electrographic) compared with placebo or no treatment (low certainty).
Barbiturate treatment showed no clear difference in abnormal neurologic exam at discharge compared with placebo or no treatment (low certainty).
The intervention probably leads to lower exchange transfusion (moderate certainty).
The intervention showed no clear difference in cerebral palsy (moderate certainty).